The hepatocyte growth factor (HGF͞SF) receptor, Met, regulates mitogenesis, motility, and morphogenesis in a cell type-dependent fashion. Activation of Met via autocrine, paracrine, or mutational mechanisms can lead to tumorigenesis and metastasis and numerous studies have linked inappropriate expression of this ligandreceptor pair to most types of human solid tumors. To prepare mAbs to human HGF͞SF, mice were immunized with native and denatured preparations of the ligand. Recloned mAbs were tested in vitro for blocking activity against scattering and branching morphogenesis. Our results show that no single mAb was capable of neutralizing the in vitro activity of HGF͞SF, and that the ligand possesses a minimum of three epitopes that must be blocked to prevent Met tyrosine kinase activation. In vivo, the neutralizing mAb combination inhibited s.c. growth in athymic nu͞nu mice of tumors dependent on an autocrine Met-HGF͞SF loop. Importantly, growth of human glioblastoma multiforme xenografts expressing Met and HGF͞SF were markedly reduced in the presence of HGF͞ SF-neutralizing mAbs. These results suggest interrupting autocrine and͞or paracrine Met-HGF͞SF signaling in tumors dependent on this pathway is a possible intervention strategy.
H
epatocyte growth factor͞scatter factor (HGF͞SF) is a multifunctional heterodimeric polypeptide produced by mesenchymal cells, and an effector of cells expressing the Met tyrosine kinase receptor (1, 2) . HGF͞SF has been shown to mediate the growth and scattering of various cell types, to mediate epithelial mesenchymal transition (3) and the formation of tubules and lumens (4, 5) , and to promote angiogenesis (6, 7) . In vivo, this ligand-receptor pair is believed to play a role in neural induction (8) , liver regeneration, wound healing (9, 10) , and normal embryological development. Both Met and HGF͞SF knockout mice are embryonic lethal and show developmental defects in the placenta, fetal liver, limb͞muscle formation, etc. (11, 12) .
In addition to the role of HGF͞SF-Met signaling in development and homeostasis, this ligand receptor has also been shown to be uniquely involved in most human solid tumors (13) and to participate in tumor development, invasion, and metastasis (14) . Met was originally isolated as the product of the human oncogene, tpr-met, which encodes an altered Met protein possessing constitutive, ligand-independent tyrosine kinase activity and transforming ability (15) . Acting through Met, HGF͞SF plays multifunctional roles on different target cells by autocrine or paracrine mechanisms, and HGF͞SF-transgenic mice develop a remarkably broad array of histologically distinct tumors of both mesenchymal and epithelial origin (16) . Met activation has also been shown to markedly enhance the metastatic spread of cancer stemming from its stimulatory influence of processes such as angiogenesis (6, 7) , cell motility (17) , and cell surface protease regulation (18, 19) . HGF͞SF has been shown to induce invasiveness in vitro in various types of tumor cells (18, 20, 21) . Neovascularization is also essential for the growth of solid tumors, and tumor cells are thought to secrete angiogenic factors that promote neovascularization. HGF͞SF is angiogenic and along with basic fibroblast growth factor has been shown to stimulate blood vessel formation directly or mediate angiogenesis through paracrine induction of vascular endothelial growth factor (VEGF) (22) . HGF͞SF also displays antiapoptotic activity (23) (24) (25) and is reported to be involved in other diseases such as cardiovascular disease and Alzheimer's disease (26, 27) .
Malignant gliomas are extremely aggressive solid tumors, and their poor prognosis is linked to their ability to induce vascular proliferation and to invade surrounding brain. Both Met and HGF͞SF are expressed in glioblastoma multiforme (GBM) (28) , and ectopic expression of HGF͞SF in GBM enhances both tumor growth and angiogenesis in vivo (29) . Moreover, HGF͞SF biological activity inhibited by a chimeric U1 small nuclear RNA͞ribozyme (30) or by the NK2 antagonist of HGF͞SF interferes with GBM growth (31) .
A rabbit polyclonal Ab can neutralize HGF͞SF (28, 32) , but there is no single mAb able to significantly inhibit all of the biological activities of HGF͞SF. Here, we describe the generation of neutralizing mAbs to HGF͞SF. We have determined that at low IgG concentration, a minimum of three mAbs used in combination are required to inhibit the Met-HGF͞SF signaling pathway in vitro. Importantly, growth in athymic nu͞nu mice of a human GBM tumor xenograft autocrine for Met and HGF͞SF is markedly inhibited with the neutralizing combination of mAbs.
Materials and Methods
Cell Lines. Madin-Darby canine kidney (MDCK) cells were cultured in DMEM supplemented with 5% FBS. S-114 cells (NIH 3T3 cells transformed with human HGF͞SF and Met; ref. 33) were grown in DMEM containing 8% of calf serum. SK-LMS-1 human leiomyosarcoma cell line (19) was maintained in DMEM containing 10% FBS. C-127 cells transformed with human HGF͞SF and mouse Met (20) , and U-118 cells (a human glioma cell line autocrine for endogenous HGF͞SF and Met; ref. 28) , were maintained in DMEM supplemented with 10% FBS. All cell lines were cultured at 37°C with 5% CO 2 .
Neutralizing mAb Production. HGF͞SF was prepared from S-114 cells and mouse mAbs against the ligand were produced by injecting BALB͞c mice i.p. with purified native and denatured (boiling in SDS sample buffer) HGF͞SF protein in complete Freund's adjuvant, followed by four additional injections in incomplete Freund's adjuvant. After 1 mo, a final HGF͞SF injection was given i.p. and i.v. without adjuvant. Polyclonal antisera from immunized mice were tested for neutralizing activity of HGF͞SF in the MDCK cell scatter assay. Spleen cells were fused with P3X63AF8͞653 myeloma cells using standard techniques 3 days after the final injection. Rabbit polyclonal Ab to HGF͞SF was used as positive control (28) .
ELISA Screening. Hybridoma cells were screened for reactivity to HGF͞SF by ELISA using 96-well plates coated with 2.5 g͞ml HGF͞SF in coating buffer (0.2 M Na 2 CO 3 ͞NaHCO 3 , pH 9.6; 50 l per well) overnight at 4°C. The plates were then blocked with PBS containing 1% BSA (200 l͞well) overnight at 4°C. Fifty microliters of hybridoma supernatant were added to wells for 1.5 h at room temperature (RT). Plates were washed twice in washing buffer (PBS with 0.05% Tween 20), and alkaline phosphatase-coupled goat anti-mouse IgG (Sigma) was added (50 l͞well) at 1:3,000 dilution for 1.5 h at RT. After washing four times in washing buffer, phosphatase substrate CPnitrophenyl phosphate (Kirkegaard & Perry Laboratories) was added for 30 min, and absorbance was measured at 405 nm. Hybridomas with strong reactivity with HGF͞SF (OD value Ͼ0.5, negative controls Ͻ0.02) were recloned twice, and reactivity was again confirmed by ELISA.
HGF͞SF Neutralization in the MDCK Scatter Assay. Recloned hybridomas supernatants, either individually or in pools, were screened for neutralizing activity to HGF͞SF using the MDCK cell scatter assay (34) . Briefly, MDCK cells were plated at 7.5 ϫ 10 4 cells per 100 l per well with or without HGF (5 ng͞well) in DMEM with 5% FBS. Three hundred microliters of supernatants (either individually or as pools), at 2-fold serial dilutions, were then added to 96-well plates. A rabbit polyclonal neutralizing antiserum (1 l͞well; ref. 28 ) was included as control. Following overnight incubation at 37°C, cells were then stained with 0.5% crystal violet in 50% ethanol (vol͞vol) for 10 min at RT, and scattering was viewed using a light microscope. The IgGs were purified from the hybridoma cell lines showing the strongest neutralizing activity by using protein G columns and were adjusted to a final concentration of 2 mg͞ml. The purified mAbs were assayed for neutralizing activity in the MDCK scatter assay.
Branching Morphogenesis Assay. Branching morphogenesis assay using SK-LMS-1 cells was conducted as described (19) . Briefly, cell suspensions were mixed with an equal volume of GFRMatrigel (Becton Dickinson), plated at 5 ϫ 10 4 cells per 125 l per well in a 96-well culture plate, and incubated for 30 min at 37°C. HGF͞SF, with or without neutralizing mAbs, was added along with DMEM containing 10% FBS on top of the gel. After 72-96 h of incubation at 37°C, representative wells were photographed at ϫ400 magnification.
HGF͞SF Immunoprecipitation and Western Blotting. S-114 cells were grown in serum-free medium for 48 h. The supernatant containing HGF͞SF was collected and precleared with normal rabbit serum and protein G-Sepharose (Sigma). One milliliter of precleared supernatant was then immunoprecipitated with 1 g of HGF͞SF mAb and 20 l of protein G-Sepharose, followed by immunoblotting as described (28) . Briefly, the immune complexes were washed, and the proteins were separated by 10% SDS͞PAGE gel and transferred onto poly(vinylidene difluoride) membrane (Bio-Rad). The membrane was blocked with PBS containing 1% BSA (Sigma) at 4°C overnight, incubated with rabbit polyclonal anti-HGF͞SF at 1:4,000 dilution for 1.5 h at RT, washed in PBS with 0.05% Tween 20, and reacted with goat anti-rabbit IgG alkaline phosphatase conjugate (Sigma) at 1:10, 000 dilution for an additional 1.5 h at RT. Following the same washing, the proteins were detected with chemiluminescent substrate as suggested by the manufacturer (Bio-Rad).
mAb Inhibition of Tumor Growth in Athymic Nude Mice. Animal experiments were performed using female athymic nude (nu͞ nu) mice at 6 weeks of age. mAb combinations (e.g., mAbs A-1, -5, and -7) prepared against native HGF͞SF were compared with nonneutralizing mAbs prepared against denatured HGF͞SF (e.g., mAbs 7-2 and -3).
C-127 cells expressing human HGF͞SF and mouse Met (35) were trypsinized, washed twice, and resuspended in PBS prior to injection. Mice were divided into five groups of five mice per group, and each mouse was injected s.c. with the cell suspension (2 ϫ 10 5 cells per 0.1 ml per mouse). The first day after cell injection, the animals were administered Abs (0.2 mg per 100 l per animal). Group one animals were injected s.c. with mAbs A-1, -5, and -7. Group 2 animals were injected i.p. with the same mAb pool. Groups 3 and 4 were injected with a combination of mAbs 7-2, -3, and -4, either s.c. or i.p., respectively. Group 5 animals received C-127 tumor cells without Abs. The Ab injections were repeated every day for 20 days, and tumor size was measured twice a week. The final data were collected when the control group was killed due to tumor size.
Xenografts of the U-118 human GBM tumor cell line, expressing HGF͞SF and Met (28) , were produced by injecting 5 ϫ 10 5 cells s.c. into seven mice per group. As in the C-127 studies above, neutralizing mAb combination A-1, -5, and -7 and nonneutralizing mAb combination 7-2 and -3 were injected twice a week (0.2 mg per 100 l͞animal) for 10 weeks after cell injection. An additional experiment was performed using the U-118 cell line to test the ability of the mAbs to interfere with the growth of established tumors. At 30 days after s.c. injection (5 ϫ 10 5 cells per mouse), mice were divided into five groups (10 mice per group) with an average tumor size about 100 mm 3 . Neutralizing (A-1, -5, and -7) and nonneutralizing (7-2 and -3) mAb combinations were injected either s.c. (intratumor) or i.p. every 2 days (0.2 mg per 100 l per mouse) for 10 weeks. Tumor size was measured twice a week, and animals were killed when the health of the animal was severely affected by the size of the tumor.
Results
Production of mAbs to HGF͞SF. We raised mAbs to both native and denatured forms of human HGF͞SF. Sera from immunized mice were tested for neutralizing activity in the MDCK scatter assay. We found that only the sera from mice immunized with native HGF͞SF inhibited scattering. After fusion, single clones of hybridoma cells positive by ELISA reactivity with HGF͞SF were selected. mAbs prepared against native and denatured HGF͞SF were tested individually for neutralizing activity in the MDCK scatter assay. No single mAb displayed neutralizing activity (data not shown). Because the sera from the mice immunized with native HGF͞SF routinely displayed neutralizing activity (data not shown), we pooled mAb culture supernatants to test for neutralization activity against HGF͞SF. One group of 10 pooled mAbs (A-1 to -10) showed strong neutralizing activity (Table 1) .
To further characterize the mAb A-1 to -10 pool, culture supernatants were produced individually, and mAbs were purified on a protein G column. Various combinations of mAbs were tested to determine which members of the pool contributed to neutralizing activity. We found that combinations of any of two mAbs of A-1 to -10 did not neutralize MDCK scattering, even when mAbs were used at molar ratios 1,000 times greater than HGF͞SF (data not shown). However, when three or more mAbs were combined, seven different combinations were identified with neutralizing activity at molar ratios of Ͻ30-fold (Table 1) . Combinations of four mAbs, which include A-1, and any three of mAbs A-4, -5, -7, or -10, had the highest neutralizing activity. However, combinations of mAb A-1, plus either A-4 or -5 and -7 or -10, also efficiently neutralized HGF͞SF-mediated MDCK scatter activity with mAbs A-1, -5, and -7 and͞or A-1, -5, and -10 showing the greatest activity (Table 1 and Fig. 1 ). The mAb series generated against denatured HGF͞SF (7-2, -3, and -4) alone or in combination did not inhibit HGF-induced scattering (Fig. 1D and data not shown) .
Branching Morphogenesis. We tested the neutralizing activity of the mAbs in the HGF͞SF-mediated branching morphogenesis assay using SK-LMS-1 cells. The mAb combinations A-1, -5, and -7 and A-1, -5, and -10 displayed the greatest inhibitory activity (Table 1) . However, A-1 is not required for blocking HGF͞SF-induced branching morphogenesis and combinations of mAbs A-4, -5, and -10 showed the highest neutralizing activity. These results suggest that a component(s) provided by the basement membrane Matrigel or the SK-LMS-1 cells abrogates the requirement for mAb A-1. The mAbs against denatured HGF 7-2 and -3 showed no neutralizing activity (data not shown).
Immunoprecipitation and Western Blot Analyses of mAbs to HGF͞SF.
The neutralizing mAbs are also very effective for immunoprecipitating native HGF͞SF from cell supernatants, whereas the mAbs raised against denatured HGF͞SF are not (mAbs 7-2, -3, or -4; Fig. 2 ). The protein migrating at Ϸ90 kDa is uncleaved HGF͞SF, and the smaller proteins represent the ␣, ␤-activated cleavage product. By contrast, the neutralizing mAbs do not recognize denatured HGF͞SF on Western blot, whereas mAbs 7-2, -3, or -4 work well (data not shown).
Antitumor Activity of HGF͞SF-Neutralizing mAbs.
We have previously demonstrated that cells with autocrine Met-HGF͞SF signaling are tumorigenetic and metastastic in nude mice (14, 18, 20) . We have characterized several human tumor types that display autocrine HGF͞SF-Met signaling, such as human osteosarcomas (32) and GBM (28) . To determine whether the neutralizing mAb to human HGF͞SF has any effect on tumors in vivo, we performed animal experiments with C-127 mouse cells created to express mouse Met and human HGF͞SF in an autocrine fashion (20) . These cells (2 ϫ 10 5 ) when injected s.c. formed tumors in athymic nude mice in 2-3 weeks. Animals injected with C-127 tumor cells were also injected with pools of either mAbs A-1, -5, and -7, or 7-2, -3, and -4, either intratumorally or i.p. every day for 20 days. The experiment was terminated at 37 days after C-127 cell injection. Dramatically, the animals treated with the combination of mAbs A-1, -5, and -7 showed 90% inhibition of tumor growth with either s.c. or i.p. mAb injection compared with the controls (Fig. 3a) .
Using the same procedure described above, we tested the mAb A-1, -5, and -7 combination in vivo in athymic nu͞nu mice with the U-118 GBM tumor cell xenograft. Human GBM cell lines coexpress HGF͞SF and Met, which is postulated to contribute to tumorigenesis. In this experiment, mAbs were injected twice in 1 week for approximately 7 weeks. Intratumor injection of the neutralizing mAb combination significantly inhibited tumor growth, whereas i.p. injection was less effective. Nevertheless, the average tumor size in the i.p. group was reduced compared with the controls (Fig. 3b) . We also tested the mAb combination 30 days after the U-118 GBM tumor growth was initiated. A significant delay in tumor growth was observed in animals receiving mAb A-1, -5, and -7 beginning on day 30 and treated every other day for up to 70 days. Although tumor regression did not occur, tumor growth was delayed (Fig. 3c) .
Discussion
Multiple biological activities of HGF͞SF are associated with its unique structure. The ligand is composed of an ␣-chain containing the N-terminal domain and four kringle domains (NK4) covalently disulfide linked to a serine protease-like ␤-chain C-terminal domain. The N-terminal hairpin domain of HGF͞SF, in combination with the first kringle domain (NK1), is able to bind the Met receptor and mediate partial activities even in the absence of the second kringle domain (NK2). NK1 shows agonistic or antagonistic activities depending on the assay system (36), whereas NK2 induces scattering, but not mitogenic activity (37) . The ␣ subunit of HGF͞SF (NK4) also binds to Met, but abrogates the mitogenic, motogenic, and morphogenic activities of HGF͞SF (38) . The biological function of the ␤ subunit of HGF͞SF has not been well characterized. Although it does not bind to the receptor alone, it has been shown that this subunit is crucial for the optimum activation of Met receptor induced by HGF͞SF (39) . Therefore, the N-terminal and the kringle domains of the ␣-chain and the ␤-chain are all required for the full spectrum of biological activity of HGF͞SF (40) . It has been shown that HGF͞SF-induced biological activities can be inhibited with rabbit polyclonal anti-HGF͞SF Ab requir- ing serum concentrations 500-to 1,000-fold greater than HGF͞SF (28, 41, 42) . By contrast, we are able to achieve HGF͞SF neutralization with mAb combinations (e.g., A-1, -5, and -7) at molar ratios 20-to 30-fold greater than HGF͞SF. Moreover, our results suggest that only certain mAbs that bind to specific epitopes of HGF͞SF can inhibit biological activity, and that blocking three or more of the epitopes is required to inhibit HGF͞SF activity. What are the characteristics of such Abs? Interestingly, none of the mAbs A-1, -4, -5, or -7 react with sulfhydryl detergent-denatured HGF͞SF after Western blot analyses, indicating that the epitopes are complex in configuration. Moreover, only two mAbs, A-4 and A-5, share epitopes (M. Fivash, M. Medaglia, and R.J.F., unpublished data). We cannot exclude that a single mAb with neutralizing activity may yet be discovered. However, among the hundreds of mAbs derived from fusions from animals with HGF͞SF-neutralizing serum, no single mAb displayed neutralizing activity. Although we have not determined the optimal concentration of each mAb in the combination, both our in vitro and in vivo results showed strong HGF͞SF-neutralizing activity with equal molar concentrations of mAb A-1, -5, and -7.
mAb A-1 recognition site is located within the NK2 domain (data not shown). Even though recognition sites for other mAbs are yet to be mapped, our results show a minimum of two additional domains of HGF͞SF must be important. mAbs A-7 and A-10 recognize unique epitopes outside of the NK2 domain (data not shown). Although we have not determined whether mAb binding to the ␤ subunit is required for neutralizing HGF͞SF, our results show that multiple ligand binding surfaces must be blocked to completely inhibit receptor activation. When any one epitope is vacant, receptor activation can take place and result in the induction of a partial, if not full, spectrum of biological effects. One possible interpretation is that ligand binding to any one site on the receptor causes a distortion in the remaining ligand epitope recognition sites displacing the mAb associated with the other sites. These results are consistent with the partial ligand activities observed with NK1 and NK2 (36, 43) . Interestingly, the three-dimensional structure of fibroblast growth factor with its receptor reveals two ligand affinity sites and one heparin binding site. Heparin bridges the ligand to the receptor through adjacent affinity sites (44) . Given the fact that HGF͞SF also has high affinity to heparin (45) and that heparin is required for Met binding and signaling (46) , the requirement for the three mAbs to neutralize HGF͞SF may indicate that this ligand also has three binding sites, two to the Met receptor and one to heparin.
Neovascularization is a key process in the growth of solid tumors, and this process is regulated by angiogenic factors. Several growth factors have been identified that are involved in tumor angiogenesis such as basic fibroblast growth factor, VEGF, and HGF͞SF (41, 42, 47) . Studies have indicated that these growth factors can have synergistic angiogenic effects. It has been shown that HGF͞SF has maximum potency for angiogenesis in the presence of basic fibroblast growth factor and VEGF (42) . Progress has been made to use neutralizing Abs of these growth factors to block their angiogenic effect. Neutralizing mAbs to basic fibroblast growth factor and VEGF are able to inhibit tumor growth in vivo in animal models (48, 49) , and anti-VEGF Abs are in Phase I clinical trials (50) . However, there has been no report on using neutralizing mAb to human HGF͞SF to study its potential antitumor effect. In this study, we demonstrate that HGF͞SF-Met signaling-mediated tumor growth in vivo can be inhibited by administering neutralizing mAb combinations to HGF͞SF. Moreover, the result of mAbmediated inhibition of GBM growth in nude mice strongly suggests that xenograft growth of this tumor depends on autocrine Met-HGF͞SF signaling.
The multiple biological functions of HGF͞SF can be neutralized by addition of a combination of specific mAbs. In vivo, these mAbs are able to inhibit the growth of tumors dependent on HGF͞SF-Met signaling in an autocrine and presumably paracrine fashion. These results suggest that interrupting autocrine and paracrine HGF͞SF signaling may be a useful intervention strategy for treating a variety of human solid tumors.
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